Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 26, 2026 08:00 ET | Source: MannKind

MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Q4 2025 revenues of $112M, +46% vs. Q4 2024 Furoscix® Q4 2025 net sales of $23M, +91% vs. Q4 2024 Afrezza® Q4 2025 net sales of $23M, +25% vs. Q4 2024 2025 full year revenues of $349M, +22% vs....
February 26, 2026 07:30 ET | Source: Custom Market Insights

[Latest] Global Laboratory Informatics Market Size/Share Worth USD 8.21 Billion by 2035 at a 5.32% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Laboratory Informatics Market Size, Trends and Insights By Product (Laboratory...
February 25, 2026 21:22 ET | Source: MindRank AI Ltd.

MindRank Announces First Patient Dosed in Phase III Trial of AI-Designed Oral GLP-1 Receptor Agonist MDR-001

MindRank, artificial intelligence (AI)-empowered drug discovery company, announced FPI in Phase III Trial of an Oral GLP-1 Receptor Agonist MDR-001.
February 25, 2026 17:12 ET | Source: kneat.com, inc.

Kneat Achieves Record Revenue for Fourth Quarter and Full Year 2025

kneat.com reports record fourth-quarter and full year 2025 results with highest-ever new customer wins in 2025.
February 25, 2026 07:00 ET | Source: George Medicines

George Medicines advances its global commercial strategy for GMRx2 with an exclusive licensing agreement with Orient EuroPharma in Southeast Asia

GMRx2 is an innovative single pill combination of three medicines designed to deliver the blood pressure-lowering benefits of triple combination therapy early in the treatment pathway, supported by an...
February 23, 2026 16:30 ET | Source: Surrozen, Inc.

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 23, 2026 08:00 ET | Source: Alps Group Inc

Alps Group Inc Publishes Clinical Safety, Tolerability and Effectiveness Data Supporting Advancement of Its Autologous NK Cell Pipeline Using an In-House Developed Culture Protocol

KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated...
February 20, 2026 08:30 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Announces Expanded IP Coverage, Strengthening Position in Biotech Evolution

NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands...
February 20, 2026 07:16 ET | Source: Research and Markets

State of the Life Sciences Industry, Q4 2025 Review - Unveils Key Trends and Opportunities in Pharma, Biopharma, Medical Devices, Cell Biology

Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The "State of the Life Sciences Industry - Fourth Quarter Review" has been added to ResearchAndMarkets.com's offering. The latest quarterly research...
February 19, 2026 09:00 ET | Source: MannKind

MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced Chief Executive Officer Michael Castagna, PharmD is...